June 2011 Monthly Message
Smithsonian Magazine Showcases Drug Development Process 
Federal Update: What's Going on in Washington 
Report Reveals New Drugs Reach Patients Sooner in the U.S. than in Europe 
Join us for the 2011 Udall Awards Dinner 
PAN CEO Amy Comstock Rick Featured on Comcast Newsmakers 
Parkinson's in the Media 
A new study  published in Health Affairs and funded by the Friends of Cancer Research shows that approval rates of oncology drug products are higher and time for review is lower in the United States than in Europe. We found this study interesting for two reasons: 1) it was an unexpected outcome; and 2) because while the results are limited to cancer treatment, they remind us to question assumptions we've made in other areas of healthcare research. This study, coupled with a letter from FDA Commissioner Margaret Hamburg  in The Washington Post earlier this year (which the study references) challenges preconceived notions in the area of global competitiveness as it relates to drug development and the regulatory environment. Click here to read the study and its results .